5 completed, 3 terminated, 1 enrolling by invitation, 1 suspended. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Suspended 1, Terminated 1 |
Follow Calibr, a division of Scripps Research: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CLF065 for Chronic Pouchitis CLF065, Placebo - Pouchitis | Phase 2 | Suspended | Calibr, a division of Scripps Research | 20 | 2026-06-01 | 2026-07-09 |
| A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases CLBR001 + SWI019 - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Withdrawn | Calibr, a division of Scripps Research | 2026-03-01 | 2026-03-05 | |
| Long Term Follow-up Study for Subjects Administered CLBR001 Long Term Follow-Up - Long Term Follow-Up | Enrolling by invitation | Calibr, a division of Scripps Research | 40 | 2025-08-28 | 2026-04-08 | |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Two Component Product CLBR001 + ABBV-461 - Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC) | Phase 1 | Terminated | Calibr, a division of Scripps Research | 10 | 2025-04-17 | 2026-05-28 |
| Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis CMR316, Placebo - Pulmonary Fibroses, Idiopathic | Phase 1 | Completed | Calibr, a division of Scripps Research | 89 | 2024-08-19 | 2026-07-09 |
| Study to Assess PDM608 in Healthy Adult Subjects PDM608, Placebo - Parkinson Disease | Phase 1 | Completed | Calibr, a division of Scripps Research | 64 | 2023-06-27 | 2025-11-18 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
| First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer CCW702 - Metastatic Castration-Resistant Prostate Adenocarcinoma | Phase 1 | Terminated | Calibr, a division of Scripps Research | 22 | 2020-07-17 | 2023-05-12 |
| A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis KA34, Placebo - Osteoarthritis, Knee | Phase 1 | Completed | Calibr, a division of Scripps Research | 60 | 2018-05-02 | 2022-12-27 |
| A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Clofazimine, Placebo - Cryptosporidiosis | Phase 2 | Terminated | University of Washington | 33 | 2017-12-14 | 2019-08-13 |
Burkitt Lymphoma (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · Arthritis (1) · Breast Neoplasms (1) · Cryptosporidiosis (1) · Idiopathic Pulmonary Fibrosis (1) · Joint Diseases (1)
Clofazimine (1)
United States (8) · Germany (1) · Malawi (1)
Martin Lotz, MD (1) · Wes Van Voorhis, MD, PhD (1)
PMID 30139372, PMID 32277809, PMID 34380625, PMID 34515338, PMID 34748385